Effects of Ridogrel, a Thromboxane Synthase Inhibitor and Receptor Antagonist, on Blood Pressure in the Spontaneously Hypertensive Rat

スポンサーリンク

概要

• 論文の詳細を見る

• Ridogrel is a dual acting thromboxane synthase inhibitor/TP receptor antagonist. We examined the effects of single and multiple doses on systolic blood pressure in stroke-prone spontaneously hypertensive rats. Single doses of ridogrel (5 to 125 mg/kg) did not affect systolic blood pressure or furosemide-stimulated excretion rates of thromboxane B<SUB>2</SUB> or 6-keto-prostaglandin F<SUB>1α</SUB>, although ex vivo serum thromboxane B<SUB>2</SUB> was dose-dependently reduced up to 95%. In contrast, repeated dosing (7 days) with ridogrel (3 to 25 mg/kg/day), had an antihypertensive effect in 12-week-old stroke-prone spontaneously hypertensive rats. At 25 mg/kg/day, ridogrel reduced systolic blood pressure from 200±6.1 to 173±6.7 mmHg (n=12, P

• 公益社団法人 日本薬理学会の論文
• 1998-12-01

著者

• Quest Dale

  Cardiovascular Risk Factor Reduction Unit (c.r.f.r. U.) Department Of Medicine Division Of Clinical

• Wilson Thomas

  Cardiovascular Risk Factor Reduction Unit (C.R.F.R. U.), Department of Medicine, Division of Clinical Pharmacology,Royal University Hospital

• Wilson Thomas

  Cardiovascular Risk Factor Reduction Unit (c.r.f.r. U.) Department Of Medicine Division Of Clinical Pharmacology Royal University Hospital

関連論文

• Effects of Ridogrel, a Thromboxane Synthase Inhibitor and Receptor Antagonist, on Blood Pressure in the Spontaneously Hypertensive Rat

スポンサーリンク